Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

NCT02784392 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Enteral Feeding Intolerance (EFI)

Interventions

DRUG: Ulimorelin
DRUG: Metoclopramide

Sponsor

Lyric Pharmaceuticals